0QQO.LSE Siegfried Holding AG
- Market cap
- GBP 321M
- P/E
- 3.3x
- P/B
- -
- ROE
- 27.4%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QQO.LSE undervalued?
Graham numberThe Graham number of Siegfried Holding AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Siegfried Holding AG fundamental analysis
No fundamental analysis for Siegfried Holding AG yet.
Siegfried Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory dis…
Full company profileSiegfried Holding AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Siegfried Holding AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 718M | 750M | 794M | 834M | 845M | 1.10B | 1.23B | 1.27B | 1.29B | 1.33B | 2.53B |
| Gross Profit | 109M | 139M | 156M | 173M | 176M | 239M | 319M | 320M | 329M | 352M | 683M |
| Operating Income | 50.3M | 58.2M | 72.7M | 54.9M | 77.4M | 130M | 228M | 175M | 192M | 210M | 350M |
| EBITDA | 92.5M | 111M | 123M | 106M | 132M | 214M | 308M | 241M | 290M | 307M | 555M |
| Net Income | 27.9M | 40.8M | 56.3M | 53.1M | 60.9M | 95.6M | 156M | 113M | 160M | 169M | 272M |
| EPS | 7.04 | 9.97 | 13 | 1.25 | 1.42 | 2.20 | 3.63 | 2.62 | 3.69 | 3.85 | 6.20 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02B | 1.07B | 1.10B | 1.17B | 1.24B | 1.67B | 1.79B | 1.86B | 1.93B | 2.15B | 2.42B |
| Total Liabilities | 361M | 403M | 424M | 733M | 747M | 1.06B | 1.08B | 1.10B | 954M | 1.03B | 1.42B |
| Shareholders' Equity | 661M | 668M | 679M | 436M | 496M | 608M | 711M | 758M | 980M | 1.13B | 995M |
| Cash & Short-term Investments | 31.6M | 34.2M | 39.9M | 25.5M | 54.4M | 73.0M | 91.6M | 56.6M | 39.6M | 104M | 105M |
| Total Debt | 407M | 356M | 366M | 391M | 377M | 560M | 590M | 445M | 490M | 575M | 925M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 44.4M | 72.4M | 95.7M | 65.6M | 115M | 120M | 142M | 209M | 160M | 222M | 359M |
| Capital Expenditure | 68.4M | 52.8M | 60.1M | 61.6M | 68.8M | 113M | 104M | 127M | 165M | 212M | 295M |
| Free Cash Flow | -24.0M | 19.6M | 35.6M | 4.02M | 46.0M | 6.65M | 38.8M | 81.2M | -5.24M | 9.97M | 64.8M |
| Ratios | |||||||||||
| ROE | 4.2% | 6.1% | 8.3% | 12.2% | 12.3% | 15.7% | 22.0% | 14.9% | 16.3% | 15.0% | 27.4% |
| ROA | 2.7% | 3.8% | 5.1% | 4.5% | 4.9% | 5.7% | 8.7% | 6.1% | 8.3% | 7.8% | 11.3% |
| Net Profit Margin | 3.9% | 5.4% | 7.1% | 6.4% | 7.2% | 8.7% | 12.7% | 8.9% | 12.4% | 12.7% | 10.8% |
| Debt to Equity | 0.62x | 0.53x | 0.54x | 0.90x | 0.76x | 0.92x | 0.83x | 0.59x | 0.50x | 0.51x | 0.93x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Siegfried Holding AG dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- 9.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 16.6M | 0.38 | 9.9% |
| 2024 | CHF 15.4M | 0.35 | 9.6% |
| 2023 | GBP 14.4M | 0.34 | 12.8% |
| 2022 | GBP 13.5M | 0.31 | 8.6% |
| 2021 | GBP 12.6M | 0.29 | 13.2% |
| 2020 | GBP 11.6M | 0.27 | 19.1% |
| 2019 | GBP 10.8M | 0.25 | 20.3% |
| 2018 | GBP 9.96M | 2.32 | 17.7% |
| 2017 | GBP 7.83M | 1.91 | 19.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Apr 28, 2025.
Who owns Siegfried Holding AG
- Insiders 13.23%
- Institutions 51.71%
- Public & others 35.06%
- Shares outstanding 4.16M
- Free float 39.9M
Siegfried Holding AG company profile
- Company name
- Siegfried Holding AG
- Ticker
- 0QQO.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 4,454
- Fiscal year end
- December
- Address
- Untere Bruehlstrasse 4, Zofingen, Switzerland, 4800
- Phone
- 41 62 746 1111
- Website
- siegfried.ch
About Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Siegfried Holding AG management
10- Mr. Marcel ImwinkelriedCEO & COO Drug Products ad interim · born 1967
- Ms. Tania Micki B.A., M.B.A.Chief Financial Officer · born 1971
- Mr. Eduardo Ricardo Santos MontanhaChief Operating Officer · born 1976
- Mr. Stefan RandlChief Scientific Officer · born 1973
- Mr. Peter StierliHead of Corporate Communications
- Ms. Olesia SilantevaChief Human Resources Officer · born 1982
- Mr. Enno Schweinberger Ph.D.Head Global Quality Management DS - Zofingen
- Beatrice HarderHead Regulatory Affairs - Site Zofingen
- John JonesHead of Operations - Malta
- Florent TrouilletHead Corporate Quality Systems - Global Quality Systems